Table 1 Clinical and demographic features of cohort
SOT cases | Non-SOT controls | P value | |
|---|---|---|---|
Median age (IQR) | 57.5 (51.3–64.0) | 58.0 (50.8–63.3) | 0.644 |
Site (%) | 0.189 | ||
Boston/BWH | 7 (8.1%) | 18 (10.2%) | |
Case Western | 2 (2.3%) | 7 (4.0%) | |
Emory | 5 (5.8%) | 12 (6.8%) | |
Florida | 3 (3.5%) | 4 (2.3%) | |
ISMMS (Mt Sinai) | 1 (1.2%) | 2 (1.1%) | |
OHSU (Oregon) | 2 (2.3%) | 3 (1.7%) | |
OUHSC (Oklahoma) | 2 (2.3%) | 0 (0.0%) | |
Stanford | 2 (2.3%) | 12 (6.8%) | |
UCLA | 40 (46.5%) | 54 (30.7%) | |
UCSF | 15 (17.4%) | 47 (26.7%) | |
Yale | 7 (8.1%) | 17 (9.7%) | |
Female sex (%) | 25 (29.1%) | 52 (29.5%) | 1.000 |
Early enrollment (%) | 39 (45.3%) | 78 (44.3%) | 0.172 |
Ethnicity (%) | 0.965 | ||
Hispanic or Latino | 49 (57.0%) | 96 (54.5%) | |
Not Hispanic or Latino | 36 (41.9%) | 79 (44.9%) | |
Not Specified | 1 (1.2%) | 1 (0.6%) | |
Race (%) | 0.393 | ||
American Indian/Alaska Native | 1 (1.2%) | 1 (0.6%) | |
Asian | 2 (2.4%) | 3 (1.7%) | |
Black/African American | 15 (17.4%) | 30 (17.0%) | |
Multiple | 1 (1.2%) | 0 (0.0%) | |
Other/Declined | 34 (39.5%) | 81 (46.0%) | |
Unknown/Unavailable | 3 (3.5%) | 2 (1.1%) | |
White | 30 (34.9%) | 59 (33.5%) | |
Trajectory group | 0.808 | ||
1 | 16 (18.6%) | 35 (20.3%) | |
2 | 20 (23.3%) | 38 (22.1%) | |
3 | 26 (30.2%) | 40 (23.3%) | |
4 | 19 (22.1%) | 52 (30.2%) | |
5 | 5 (5.8%) | 7 (4.1%) | |
ICU admission (%) | 32 (37.2%) | 64 (37.2%) | 1.00 |
Ever intubated (%) | 17 (19.3%) | 42 (23.4%) | 0.497 |
Mortality (%) | |||
D28 | 5 (5.8%) | 7 (4.1%) | 0.754 |
Ever | 12 (14.0%) | 20 (11.6%) | 0.739 |
Diabetes (%) | 38 (44.2%) | 55 (32.0%) | 0.074 |
Steroids (%) | 76 (88.4%) | 104 (60.5%) | 8.3e-6 |
Remdesivir (%) | 57 (66.3%) | 124 (72.1%) | 0.414 |
